What Maine Medicaid actually covers for Wegovy, Zepbound, Ozempic and Mounjaro. Most state Medicaid programs still exclude weight-loss-indication GLP-1, but the diabetes path is covered nearly everywhere with prior authorization (your doctor asks the plan to approve it first). Here is the current 2026 reality for Maine.
Coverage summary
| Indication | Coverage |
|---|---|
| Wegovy (weight loss) | No |
| Zepbound (weight loss) | Limited |
| Ozempic / Mounjaro (type 2 diabetes) | Yes |
| Compounded semaglutide / tirzepatide | No |
Prior-authorization criteria
These rules come from the state preferred drug list (PDL), the list of drugs Maine Medicaid has agreed to pay for.
| Criterion | Value |
|---|---|
| PA burden | Medium |
| BMI threshold (weight-loss path) | Not applicable (weight-loss path not covered) |
| Comorbidity required | No |
| Last PDL update reviewed | 2026-01-01 |
What this means in practice
MaineCare does not cover Wegovy for weight loss alone. It is covered for heart protection: BMI over 27 plus a prior heart attack, stroke or symptomatic peripheral artery disease (poor leg circulation), and the request must not be for weight loss only (PDL effective January 1, 2026). Zepbound is covered only for obstructive sleep apnea.
Managed-care organizations in Maine
Maine Medicaid operates primarily as fee-for-service. PA submissions go directly to the state Medicaid pharmacy benefit administrator rather than to a contracted managed-care organization (MCO), the kind of private health plan that runs Medicaid coverage in most states.
Cash-pay alternatives if Medicaid does not cover you
If BMI is below 35 or comorbidity is not documented, the diabetes path applies for T2D. See /best/cheapest/.
If you end up paying cash, the GLP-1 cost guide breaks down what every legitimate path actually costs at maintenance dose, from the $149-a-month compounded floor to branded manufacturer-direct pricing. For ranked cash-pay options, see programs ranked by price and programs under $150 a month. For manufacturer patient-assistance routes that bypass insurance entirely, see every cost-reduction pathway in 2026. For manufacturer savings cards and the Medicare Bridge, see the GLP-1 coupons and savings guide.
Take it to your prescriber: PA letter library
If you qualify under one of the covered indications above, the prior-authorization route is the cheapest path. We maintain a PA letter library with templates for Aetna, Cigna, UnitedHealthcare, Anthem BCBS, Kaiser, Humana, Tricare, FEHB and Medicare Advantage, cross-indexed against six qualifying clinical pictures. Each template cites the plan's policy document, the qualifying ICD-10 codes and the registration-trial evidence.
If you have type 2 diabetes plus chronic kidney disease and established cardiovascular disease, the triple-indication evidence stack (FLOW + SELECT + SUSTAIN-6) is the strongest PA path in any state.
If your PA is denied, the appeal letter library has denial-specific templates. For the commercial and Medicare coverage paths, see the GLP-1 insurance guide.
Maine Medicaid GLP-1 FAQ
Does Maine Medicaid cover Wegovy for weight loss?
Does Maine Medicaid cover Zepbound for weight loss?
Does Maine Medicaid cover Ozempic or Mounjaro for diabetes?
What if Maine Medicaid does not cover my GLP-1?
Other state Medicaid pages
See the full 51-state coverage table for the side-by-side view across every US state.
How we built this page
Compiled from each state Medicaid's published preferred drug list, PA criteria and PDL committee minutes. State Medicaid programs are not federally required to cover obesity drugs; the diabetes indication is covered nearly everywhere with PA. State-level data is point-in-time and shifts each PDL cycle. Always verify with your state Medicaid plan before relying on this page.
Last updated: 2026-07-13. We check each state Medicaid PDL and PA criteria quarterly. If you have recently had a different experience with Maine Medicaid, email hello@glpchart.com with the details and we will check it.
